These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 7912873)
21. [Mechanism of action of gold in treatment of rheumatoid arthritis]. Burmester GR; Barthel HR Z Rheumatol; 1996; 55(5):299-306. PubMed ID: 9036716 [TBL] [Abstract][Full Text] [Related]
22. [2 cases of fibrosing alveolitis in patients with rheumatoid arthritis treated with chrysanol]. Repnitskaia ZD; Sunegin KB Klin Med (Mosk); 1990 Sep; 68(9):99-100. PubMed ID: 1981247 [No Abstract] [Full Text] [Related]
23. Infusion reaction to infliximab in a patient with rheumatoid arthritis after discontinuation over 1 year and readministration. Toki H; Momohara S; Tsukahara S; Ikari K J Rheumatol; 2008 Sep; 35(9):1896-7; author reply 1897. PubMed ID: 18785300 [No Abstract] [Full Text] [Related]
24. [Gold preparations in therapy of rheumatoid and psoriatic arthritis]. Nasonova VA; Lukina GV; Sigidin IaA; Badokin VV Ter Arkh; 2003; 75(5):88-90. PubMed ID: 12847908 [No Abstract] [Full Text] [Related]
25. [Gold-induced pulmonary disease: clinical features, outcomes, and differentiation from rheumatoid lung disease]. Schnabel A Pneumologie; 1997 Sep; 51(9):921. PubMed ID: 9411445 [No Abstract] [Full Text] [Related]
26. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722 [TBL] [Abstract][Full Text] [Related]
27. Current tumor necrosis factor-alpha inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis. Liang GC; Cordero M; Dyer A; Chang RW J Rheumatol; 2005 Sep; 32(9):1662-5. PubMed ID: 16142857 [TBL] [Abstract][Full Text] [Related]
28. Technetium-99m labelled polyclonal human IgG scintigraphy before and 26 weeks after initiation of parenteral gold treatment in patients with rheumatoid arthritis. de Bois MH; Westedt ML; Arndt JW; Wiarda KS; van der Velde EA; Pauwels EK; Breedveld FC J Rheumatol; 1995 Aug; 22(8):1461-5. PubMed ID: 7473466 [TBL] [Abstract][Full Text] [Related]
29. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Bliddal H; Terslev L; Qvistgaard E; Konig M; Holm CC; Rogind H; Boesen M; Danneskiold-Samsøe B; Torp-Pedersen S Scand J Rheumatol; 2006; 35(5):341-5. PubMed ID: 17062431 [TBL] [Abstract][Full Text] [Related]
31. Long-term cyclosporin continuation rates in rheumatoid arthritis patients. Carpentier N; Bertin P; Druet-Cabanac M; Abdeddaïm M; Vergne P; Bonnet C; Trèves R Rev Rhum Engl Ed; 1999 May; 66(5):245-9. PubMed ID: 10380255 [TBL] [Abstract][Full Text] [Related]
32. [Unusual cutaneous angiofibromatosis following gold therapy of primary chronic polyarthritis]. Herbst WM; Hornstein OP; Griessmeyer G Hautarzt; 1989 Sep; 40(9):568-72. PubMed ID: 2572572 [TBL] [Abstract][Full Text] [Related]
33. [An evaluation of the results of the long-term treatment of rheumatoid arthritis patients with gold salts, aminoquinoline preparations and nonsteroidal anti-inflammatory preparations]. Ivanova MM; Karateev DE; Shakirova MR; Smirnov AV Ter Arkh; 1997; 69(5):27-32. PubMed ID: 9235650 [No Abstract] [Full Text] [Related]
34. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM; J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184 [TBL] [Abstract][Full Text] [Related]
35. [A method for the permanent maintainance aurotherapy of rheumatoid arthritis patients under the control of gold excretion]. Ornat SIa; Aleksandruk DP Lik Sprava; 1992 May; (5):43-6. PubMed ID: 1359710 [TBL] [Abstract][Full Text] [Related]
36. Infliximab: additional safety data from an open label study. Daniel CL; Moreland LW J Rheumatol; 2002 Apr; 29(4):647-9. PubMed ID: 11950000 [No Abstract] [Full Text] [Related]
37. Variability in individual responses of 532 patients with rheumatoid arthritis to first-line and second-line drugs. Pincus T; Callahan LF Agents Actions Suppl; 1993; 44():67-75. PubMed ID: 8103964 [TBL] [Abstract][Full Text] [Related]
38. Hepatotoxicity of parenteral gold therapy in rheumatoid arthritis: a case report and review of the literature. te Boekhorst PA; Barrera P; Laan RF; van de Putte LB Clin Exp Rheumatol; 1999; 17(3):359-62. PubMed ID: 10410273 [TBL] [Abstract][Full Text] [Related]
39. A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritis. Lipani JA; Strand V; Woodworth T; Furst D; Singh G; Johnson K; Day R; Brooks P J Rheumatol; 2000 Apr; 27(4):827-30. PubMed ID: 10782801 [No Abstract] [Full Text] [Related]
40. Subtherapeutic dosing of methotrexate in rheumatoid arthritis trials. Parker CT; Mewshaw E; Dennis GJ J Am Osteopath Assoc; 2004 Jan; 104(1):7-8. PubMed ID: 14992316 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]